Methods for assaying gene imprinting and methylated CpG islands
Genomic imprinting is a parent of origin-dependent gene silencing that involves marking of alleles in the germline and differential expression in somatic cells of the offspring. Imprinted genes and abnormal imprinting have been implicated in development, human disease, and embryonic stem cell transplantation. We have established a model system for genomic imprinting using pluripotent 8.5 d.p.c. mouse embryonic germ (EG) cell lines derived from an interspecific cross. We find that allele-specific imprinted gene expression has been lost in these cells. However, partial restoration of allele-specific silencing can occur for some imprinted genes after in vitro differentiation of EG cells into somatic cell lineages, indicating the presence of a gametic memory that is separable from allele-specific gene silencing. We have also generated a library containing most methylated CpG islands. A subset of these clones was analyzed and revealed a subdivision of methylated CpG islands into 4 distinct subtypes: CpG islands belonging to high copy number repeat families; unique CpG islands methylated in all tissues; unique methylated CpG islands that are unmethylated in the paternal germline; and unique CpG islands methylated in tumors. This approach identifies a methylome of methylated CpG islands throughout the genome.
1. A method of providing an assessment of risk of developing cancer, comprising:
determining methylation status of at least one CpG island selected from the group identified in Table 2 in a sample of a patient;
comparing the methylation status of the CpG island to that found in a control group of healthy individuals; and
identifying the patient as having an increased risk of developing cancer if the methylation status of the CpG island is perturbed relative to the methylation status relative to the control group.
2. The method of claim 1 , wherein the status of at least 5 CpG islands is determined and the patient is identified as having an increased risk of developing cancer if at least 3 of said CpG islands have perturbed methylation status relative to the control group.
3. A method of providing diagnostic information relative to cancer, comprising:
determining methylation status of at least one CpG island selected from the group identified in Table 2 in a sample of a tissue of a patient suspected of being neoplastic;
comparing the methylation status of the CpG island to that found in a control sample of said tissue which is apparently normal; and
identifying the patient as having an increased risk of developing cancer if methylation status of the CpG island is perturbed relative to the methylation status in the control sample.
4. The method of claim 3 wherein the status of at least 5 CpG islands is determined and the patient is identified as having an increased risk of developing in cancer if at least 3 of said CpG islands have perturbed methylation status relative to the control sample.
5. The method of claim 1 , wherein the status of at least 2 CpG islands is determined and the patient is identified as having an increased risk of developing cancer if at least 1 of said CpG islands have perturbed methylation status relative to the control group.
6. The method of claim 3 , wherein the status of at least 2 CpG islands is determined and the patient is identified as having an increased risk of developing cancer if at least 1 of said CpG islands have perturbed methylation status relative to the control group.
7. The method of claim 1 , wherein the cancer is a tumor.
8. The method of claim 3 , wherein the cancer is a tumor.